These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
734 related articles for article (PubMed ID: 12185503)
81. [Monoclonal gammopathies of undetermined significance do not systematically require a specialized consultation]. Fouquet G; Amouzou K; Renaud L; Carpentier B; Simonnet A; Van de Wyngaert Z; Guidez S; Demarquette H; Seynave M; Deleplanque D; Yakoub-Agha I; Facon T; Leleu X Rev Med Interne; 2015 Jul; 36(7):444-9. PubMed ID: 25596921 [TBL] [Abstract][Full Text] [Related]
82. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520 [TBL] [Abstract][Full Text] [Related]
83. [Rapid development of primary amyloidosis after two years' follow-up of monoclonal gammopathy of undetermined significance (MGUS)]. Kanoh T; Inoue M; Okuma M Rinsho Ketsueki; 1993 Aug; 34(8):952-6. PubMed ID: 8411650 [TBL] [Abstract][Full Text] [Related]
84. Monoclonal gammopathy after liver transplantation: a risk factor for long-term medical complications other than malignancies. Galioto A; Morando F; Rosi S; Schipilliti M; Fasolato S; Magrin M; Frigo AC; Adami F; Cavallin M; Zanus G; Plebani M; Romano A; Sticca A; Cillo U; Gatta A; Angeli P Transpl Int; 2012 Jan; 25(1):25-33. PubMed ID: 21999283 [TBL] [Abstract][Full Text] [Related]
85. Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance. Goebel TE; Schiltz NK; Woodside KJ; Pillai AC; Caimi PF; Lazarus HM; Koroukian SM; Campagnaro EL Clin Transplant; 2015 Sep; 29(9):851-7. PubMed ID: 26194021 [TBL] [Abstract][Full Text] [Related]
86. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY; Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800 [TBL] [Abstract][Full Text] [Related]
87. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Corso A; Arcaini L; Mangiacavalli S; Astori C; Orlandi E; Lorenzi A; Passamonti F; Klersy C; Pascutto C; Canevari-Sciorati A; Lazzarino M Haematologica; 2001 Apr; 86(4):394-8. PubMed ID: 11325645 [TBL] [Abstract][Full Text] [Related]
88. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance. Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064 [TBL] [Abstract][Full Text] [Related]
89. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Golombick T; Diamond TH; Manoharan A; Ramakrishna R Am J Hematol; 2012 May; 87(5):455-60. PubMed ID: 22473809 [TBL] [Abstract][Full Text] [Related]
90. Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important. Berenson JR; Yellin O Clin Lymphoma Myeloma; 2009 Aug; 9(4):311-5. PubMed ID: 19717382 [TBL] [Abstract][Full Text] [Related]
91. [Pitfalls of monoclonal gammopathy]. Meuleman N Rev Med Brux; 2013 Sep; 34(4):335-8. PubMed ID: 24195249 [TBL] [Abstract][Full Text] [Related]
92. Fracture risk in patients with monoclonal gammopathy of undetermined significance. Gregersen H; Jensen P; Gislum M; Jørgensen B; Sørensen HT; Nørgaard M Br J Haematol; 2006 Oct; 135(1):62-7. PubMed ID: 16925792 [TBL] [Abstract][Full Text] [Related]
93. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E; Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884 [No Abstract] [Full Text] [Related]
94. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Bataille R; Jourdan M; Zhang XG; Klein B J Clin Invest; 1989 Dec; 84(6):2008-11. PubMed ID: 2592570 [TBL] [Abstract][Full Text] [Related]
95. [Monoclonal gammopathies of undetermined significance. Clinical course and biological aspects of 397 cases]. Giraldo MP; Rubio-Félix D; Perella M; Gracía JA; Bergua JM; Giralt M Sangre (Barc); 1991 Oct; 36(5):377-82. PubMed ID: 1816635 [TBL] [Abstract][Full Text] [Related]
96. Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance. Manson GV; Campagnaro E; Balog A; Kaplan D; Sommers SR; Fu P; Rajkumar SV; Lazarus HM Bone Marrow Transplant; 2012 Sep; 47(9):1212-6. PubMed ID: 22158387 [TBL] [Abstract][Full Text] [Related]
97. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS). Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315 [TBL] [Abstract][Full Text] [Related]